Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure (Q43582917)

24 November 2017

title

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure (English)

1 reference

24 November 2017

1 reference

8

1 reference

24 November 2017

9

1 reference

24 November 2017

Armando Santoro

6

1 reference

ORCID Public Data File 2021

Luigi Dogliotti

7

object named as

Luigi Dogliotti

1 reference

24 November 2017

11

Cora N Sternberg

1 reference

24 November 2017

Hielke J Meulenbeld

1

1 reference

24 November 2017

Jean P Bleuse

2

1 reference

24 November 2017

Elio M Vinci

3

1 reference

24 November 2017

Eric Raymond

4

1 reference

24 November 2017

Giordano Vitali

5

1 reference

24 November 2017

Scott T Tagawa

10

1 reference

24 November 2017

Maria G Jannuzzo

12

1 reference

24 November 2017

Mariangela Mariani

13

1 reference

24 November 2017

Anna Petroccione

14

1 reference

24 November 2017

Ronald de Wit

15

1 reference

24 November 2017

publication date

29 August 2012

1 reference

24 November 2017

1 reference

24 November 2017

volume

111

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

44-52

1 reference

The current state of hormonal therapy for prostate cancer

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Targeting Aurora kinases for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Prostate cancer in a transgenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Understanding the lethal variant of prostate cancer: power of examining extremes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

A phase II clinical trial of sorafenib in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2012.11404.X

10.1111/J.1464-410X.2012.11404.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference